This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
CRD summary
The study examined cost-effectiveness of routine postoperative administration of vitamin D or metabolites and calcium to reduce the incidence of hypocalcaemia after total thyroidectomy. The authors concluded that both supplementation strategies were cost-effective compared to no intervention and should be recommended as routine prophylactic treatments for this patient population. The analysis used a clear and transparent cost-effectiveness analysis. The authors' conclusions appear robust.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The study examined the cost-effectiveness of routine postoperative administration of vitamin D or metabolites and calcium to reduce the incidence of hypocalcaemia after total thyroidectomy.
Interventions
Three strategies were compared for prophylaxis of hypocalcaemia: no supplementation; routine oral supplementation with calcitriol plus calcium treatment; and routine oral supplementation with exclusive calcium treatment.
Location/setting
Colombia/secondary care.
Methods

Analytical approach:
The analysis was based on a decision tree model with a one-month time horizon. The authors stated they adopted the perspective of a health management organisation.
Effectiveness data:
Clinical inputs were taken from a previously published systematic review that included 706 patients: 346 in the vitamin D plus calcium group; 288 in the oral calcium group; and 72 in the control group (no treatment). The systematic review included only randomised clinical trials. Odds ratios were calculated for the comparison between the two prophylactic groups as compared to no treatment. The primary endpoint was presence or absence of symptomatic postoperative hypocalcaemia.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
The summary benefit measure was defined as the proportion of patients without symptomatic postoperative hypocalcaemia.
Cost data:
The economic analysis included costs of medications (calcitriol, calcium carbonate, calcium gluconate) and medical services (emergency department visits, serum calcium measurement, hospitalisation). Costs born during both the acute
